Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Hims & Hers, which markets compounded versions of semaglutide through its telehealth platform, released clinical data shortly after Novo’s statement. The data showed that users of its compounded GLP-1 ...

Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its ...

Novo Nordisk faces a significant market value drop amid competition and leadership changes. Maziar Mike Doustdar has been ...

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

A growing number of people are turning to medications like Ozempic, Wegovy, and Mounjaro to aid in weight loss and manage ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

Novo Nordisk falls as company slashes 2025 forecasts as US sales of Wegovy and Ozempic face headwinds from compounded drugs.